Platinum Priority – Kidney CancerEditorial by Umberto Capitanio and Alessandro Volpe on pp. 1014–1015 of this issueRenal Tumor Biopsy for Small Renal Masses: A Single-center 13-year Experience☆
Introduction
The incidence of kidney cancer is increasing, primarily due to an increase in the detection of small renal masses (SRMs) that are often early stage renal cell carcinomas (RCCs) [1]. This is thought to be in large part related to the greater use of abdominal imaging [2].
Surgical treatment of stage pT1a RCC produces excellent cancer-specific survival rates [3]. Most are incidentally detected as SRMs that are usually solid enhancing masses on imaging and concerning for malignancy [2]. There are currently no clinical or radiographic features that accurately predict histologic diagnosis. Hence surgical series have shown that 20–30% of SRMs are benign on final pathology. Moreover, SRMs found to be malignant are usually of lower nuclear grade than their larger counterparts [4].
Renal tumor biopsies (RTBs) have been proposed as a safe and useful tool for the pretreatment identification of benign tumors. The goal of RTB is to avoid the potential morbidity associated with overtreatment of SRMs [5], [6], [7], [8]. Despite their potential benefits, RTBs have not been widely adopted in the management of SRMs [9]. The lag in uptake is likely due to concerns regarding the lack of sufficient tissue for diagnosis, discordance with final pathology, safety, and, most importantly, the lack of perceived impact on clinical management. Several, albeit generally small, studies suggest that these concerns were exaggerated [5], [6], [7], [8]. However, large series that demonstrate the benefits of RTB are currently lacking.
In this study, we described the largest single-institution experience with RTB of SRMs, explored factors associated with diagnostic success, and assessed the impact of RTB on clinical management.
Section snippets
Patient selection
This retrospective single-center study was approved by the institutional review board. Subjects who underwent an RTB for a radiologically indeterminate SRM between January 2001 and December 2013 were identified through a prospectively maintained database. A chart review was completed to abstract periprocedural complications and to exclude predominantly cystic lesions as well as RTBs that were not performed with the objective of aiding treatment planning.
A total of 705 RTBs performed in patients
Results
A total of 529 biopsied SRMs in 509 patients were included in the analysis. The initial biopsy was diagnostic in 90% (n = 476). Of these, 26% (n = 123) were of benign histology. The patient, procedure, and lesion characteristics of initial diagnostic and nondiagnostic biopsies are compared in Table 1. Of the 53 nondiagnostic RTBs, a rebiopsy was performed in 24 masses (45%) and was diagnostic in 83% (n = 20) of them (Fig. 1). Therefore, the overall diagnostic rate when the first and second RTBs were
Discussion
Despite a growing body of evidence, the merits and safety of pretreatment biopsy continue to be debated. This study focused on RTB of SRMs as an aid to treatment decision making. To the best of our knowledge, it is the largest single-institution cohort published on SRM biopsy. We have demonstrated a 90% diagnostic rate with an initial biopsy and an 83% diagnostic rate after a rebiopsy for initially nondiagnostic RTB. Thus RTBs led to a diagnosis in 94% of patients with SRMs when the outcomes
Conclusions
Although the evidence in favor of routine RTB to characterize SRMs is compelling, critics have continued to argue against the practice because of the previously enumerated concerns. Our results demonstrate that each of these concerns is exaggerated. In view of our results, it seems difficult to continue to justify a timid uptake of routine SRM biopsies and the use of this information to implement treatment strategies. Indeed RCC is one of the very few tumors where indications for surgery are
References (29)
- et al.
Outcomes of small renal mass needle core biopsy, nondiagnostic percutaneous biopsy, and the role of repeat biopsy
Eur Urol
(2011) - et al.
Techniques, safety and accuracy of sampling of renal tumors by fine needle aspiration and core biopsy
J Urol
(2007) - et al.
Prognostic and therapeutic impact of histopathologic definition of parenchymal epithelial renal tumors
Eur Urol
(2010) - et al.
Can renal biopsy accurately predict histological subtype and Fuhrman grade of renal cell carcinoma?
J Urol
(2012) - et al.
Accuracy and clinical role of fine needle percutaneous biopsy with computerized tomography guidance of small (less than 4.0 cm) renal masses
J Urol
(2004) - et al.
The value of preoperative needle core biopsy for diagnosing benign lesions among small, incidentally detected renal masses
J Urol
(2008) - et al.
Rationale for percutaneous biopsy and histologic characterisation of renal tumours
Eur Urol
(2012) - et al.
Accuracy of determining small renal mass management with risk stratified biopsies: confirmation by final pathology
J Urol
(2013) - et al.
Solid renal tumors: an analysis of pathological features related to tumor size
J Urol
(2003) - et al.
Active surveillance of small renal masses: progression patterns of early stage kidney cancer
Eur Urol
(2011)
Comparison of 1,800 laparoscopic and open partial nephrectomies for single renal tumors
J Urol
Comparison between open partial and radical nephrectomy for renal tumours: perioperative outcome and health-related quality of life
Eur Urol
The natural history of incidentally detected small renal masses
Cancer
Cited by (0)
- ☆
Please visit www.eu-acme.org/europeanurology to read and answer questions on-line. The EU-ACME credits will then be attributed automatically.